Yasaman Barekatain
Overview
Explore the profile of Yasaman Barekatain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahadevan K, McAndrews K, LeBleu V, Yang S, Lyu H, Li B, et al.
Cancer Cell
. 2023 Aug;
41(9):1606-1620.e8.
PMID: 37625401
The KRAS mutation is present in nearly half of pancreatic adenocarcinomas (PDAC). We investigated the effects of inhibiting the KRAS mutant protein with MRTX1133, a non-covalent small molecule inhibitor of...
2.
Khadka S, Lin Y, Ackroyd J, Chen Y, Sheng Y, Qian W, et al.
bioRxiv
. 2023 May;
PMID: 37214825
Tumor angiogenesis is a cancer hallmark, and its therapeutic inhibition has provided meaningful, albeit limited, clinical benefit. While anti-angiogenesis inhibitors deprive the tumor of oxygen and essential nutrients, cancer cells...
3.
Mahadevan K, McAndrews K, LeBleu V, Yang S, Lyu H, Li B, et al.
bioRxiv
. 2023 Feb;
PMID: 36824971
Pancreatic ductal adenocarcinoma (PDAC) is associated with mutations in Kras, a known oncogenic driver of PDAC; and the mutation is present in nearly half of PDAC patients. Recently, a non-covalent...
4.
Yan V, Barekatain Y, Lin Y, Satani N, Hammoudi N, Arthur K, et al.
ACS Pharmacol Transl Sci
. 2023 Feb;
6(2):245-252.
PMID: 36798479
Metabolically labile prodrugs can experience stark differences in catabolism incurred by the chosen route of administration. This is especially true for phosph(on)ate prodrugs, in which successive promoiety removal transforms a...
5.
Yan V, Pham C, Ballato E, Yang K, Arthur K, Khadka S, et al.
J Med Chem
. 2022 Oct;
65(20):13813-13832.
PMID: 36251833
Cancers harboring homozygous deletion of the glycolytic enzyme enolase 1 () are selectively vulnerable to inhibition of the paralogous isoform, enolase 2 (ENO2). A previous work described the sustained tumor...
6.
Barekatain Y, Khadka S, Harris K, Delacerda J, Yan V, Chen K, et al.
Anal Chem
. 2022 Jul;
94(28):10045-10053.
PMID: 35792073
The phosphonate group is a key pharmacophore in many antiviral, antimicrobial, and antineoplastic drugs. Due to its high polarity and short retention time, detecting and quantifying such phosphonate-containing drugs with...
7.
Miller J, Shah I, Hatten J, Barekatain Y, Mueller E, Moustafa A, et al.
Elife
. 2021 Nov;
10.
PMID: 34821554
No abstract available.
8.
Jezewski A, Lin Y, Reisz J, Culp-Hill R, Barekatain Y, Yan V, et al.
Front Cell Infect Microbiol
. 2021 Oct;
11:730413.
PMID: 34604112
Glycolysis controls cellular energy, redox balance, and biosynthesis. Antiglycolytic therapies are under investigation for treatment of obesity, cancer, aging, autoimmunity, and microbial diseases. Interrupting glycolysis is highly valued as a...
9.
Miller J, Shah I, Hatten J, Barekatain Y, Mueller E, Moustafa A, et al.
Elife
. 2021 Jul;
10.
PMID: 34279224
Carboxy ester prodrugs are widely employed to increase oral absorption and potency of phosphonate antibiotics. Prodrugging can mask problematic chemical features that prevent cellular uptake and may enable tissue-specific compound...
10.
Barekatain Y, Ackroyd J, Yan V, Khadka S, Wang L, Chen K, et al.
Nat Commun
. 2021 Jul;
12(1):4228.
PMID: 34244484
Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as glioblastoma represents a potentially targetable vulnerability. Homozygous MTAP-deleted cell lines in culture show elevation of MTAP's substrate metabolite, methylthioadenosine (MTA)....